Emerald Mutual Fund Advisers Trust lowered its position in Bluebird Bio Inc. (NASDAQ:BLUE) by 27.6% during the second quarter, Holdings Channel reports. The institutional investor owned 153,610 shares of the company’s stock after selling 58,475 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Bluebird Bio were worth $6,650,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Seven Eight Capital LLC bought a new position in Bluebird Bio during the first quarter worth $108,000. Legal & General Group Plc boosted its position in Bluebird Bio by 31.6% in the first quarter. Legal & General Group Plc now owns 2,895 shares of the company’s stock worth $123,000 after buying an additional 695 shares in the last quarter. BlackRock Inc. boosted its position in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock worth $194,000 after buying an additional 3,533 shares in the last quarter. OMERS ADMINISTRATION Corp boosted its position in Bluebird Bio by 1.7% in the first quarter. OMERS ADMINISTRATION Corp now owns 6,000 shares of the company’s stock worth $255,000 after buying an additional 100 shares in the last quarter. Finally, Capital Fund Management S.A. boosted its position in Bluebird Bio by 1,233.8% in the second quarter. Capital Fund Management S.A. now owns 6,803 shares of the company’s stock worth $295,000 after buying an additional 7,403 shares in the last quarter.
Shares of Bluebird Bio Inc. (NASDAQ:BLUE) traded down 0.47% on Friday, reaching $69.67. 940,729 shares of the company’s stock traded hands. Bluebird Bio Inc. has a 52 week low of $35.37 and a 52 week high of $99.70. The stock’s 50-day moving average price is $61.41 and its 200-day moving average price is $49.93. The stock’s market capitalization is $2.59 billion.
Bluebird Bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.15. The company had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. Bluebird Bio’s revenue for the quarter was down 68.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.57) earnings per share. Equities analysts predict that Bluebird Bio Inc. will post ($6.19) EPS for the current year.
A number of research firms have weighed in on BLUE. Maxim Group set a $85.00 price objective on shares of Bluebird Bio and gave the stock a “buy” rating in a research report on Thursday, September 22nd. Leerink Swann restated a “buy” rating on shares of Bluebird Bio in a research report on Monday, June 13th. Wedbush restated an “outperform” rating and set a $117.00 price objective on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Zacks Investment Research cut shares of Bluebird Bio from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Piper Jaffray Cos. set a $95.00 target price on shares of Bluebird Bio and gave the company a “buy” rating in a research report on Thursday, September 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $90.25.
In other Bluebird Bio news, insider David Davidson sold 1,000 shares of the business’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the sale, the insider now directly owns 10,600 shares in the company, valued at approximately $477,848. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sullivan sold 2,807 shares of the business’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $45.04, for a total transaction of $126,427.28. Following the sale, the insider now owns 4,656 shares in the company, valued at $209,706.24. The disclosure for this sale can be found here. Company insiders own 3.50% of the company’s stock.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bluebird Bio Inc. (NASDAQ:BLUE).
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.